ClinicalTrials.gg
RecruitingNCT07896252AERODUO-2Updated Oct 28, 2026

Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients

A Phase 2 interventional study of AERO-001 and AERO-002 in COPD, Chronic Obstructive Pulmonary Disease (COPD) and Lung Disease Chronic, sponsored by AeroRx Therapeutics Inc.. Recruiting at 2 sites in United Kingdom. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by AeroRx Therapeutics Inc. · Phase 2, Interventional, and Treatment

Updated Oct 28, 2026Now RecruitingFirst site in United Kingdom+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 620 studies in Pulmonary Disease, Chronic Obstructive with a site in United Kingdom — 59 open to participants now, 75 under way, 10 of them phase 3. Pulmonary Disease, Chronic Obstructive · United Kingdom.

Planned enrollment
253rd of 465
64 · median 80
Started
2026
with 15 others
Phase 2
91 of 620
4 open now
Primary completion
2027-06
later than 45 of 74 live
Registered
619th of 620
by date

Among the 620 studies in Pulmonary Disease, Chronic Obstructive with a site in United Kingdom, this one is the 253rd largest by planned enrollment of the 465 interventional ones that give a count, is one of 16 that started in 2026, is one of 91 in phase 2, reaches primary completion later than 45 of the 74 other live ones, and was the 619th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

59 of the 620 studies in Pulmonary Disease, Chronic Obstructive with a site in United Kingdom are open now. Recruiting first, the newest first:

53 more — sign in →

All 59 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 620 studies in Pulmonary Disease, Chronic Obstructive with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging,14-day dosing, 2-period crossover study in participants with chronic obstructive pulmonary disease (COPD).

Read the detailed description

Combination of a long-acting beta-agonist (LABA) bronchodilator and a long-acting muscarinic antagonist (LAMA) bronchodilator is the preferred choice for initial therapy for patients with chronic obstructive pulmonary disease (COPD). Although there are currently multiple LABA+LAMA combination bronchodilators available in metered dose inhalers (MDIs), dry powder inhalers (DPI), and soft mist inhalers (SMI), a significant percentage of COPD patients, generally high risk and older patients, do not receive optimal benefit from inhalers.

Nebulized delivery provides an effective alternative where disease management is sub optimal. To date there are no approved LABA+LAMA combinations available by nebulization.

AERO-007 is a propriety inhalation solution formulation of fixed-dose combination of LABA+LAMA (indacaterol, AERO-001 and glycopyrrolate, AERO-002) for delivery in a general purpose nebulizer device. A phase 2a, single-dose, dose-ranging study of AERO-007 has been completed in participants with COPD at two dose levels (100/50 µg and 200/100 µg). AERO-007 at both low and high doses was well tolerated with robust, clinically meaningful and statistically significant bronchodilation with rapid onset of action that was sustained for 24 hours.

The objective of this phase 2b study is to determine the optimal doses of the monotherapy components of AERO-007 and to assess the safety, PK and bronchodilation profile of AERO-007 following 14 days of dosing in participants with COPD.

03

Conditions studied

  • COPD
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Lung Disease Chronic
  • Lung Diseases, Obstructive

Keywords

  • COPD
  • LABA+LAMA
  • Inhalation
  • Nebulization
  • General purpose nebulizer
  • Bronchodilation
  • FEV1
  • Pharmacokinetics
  • Phase 2b
  • Safety
  • Efficacy
  • Randomized
  • Double-blind
  • Placebo-controlled
  • 2-period crossover
  • Indacaterol
  • Glaycopyrrolate
  • LABA
  • LAMA
  • AeroRx
  • AERO-007
  • Dose ranging
  • indacaterol+glycopyrrolate
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 40 to 75 years, inclusive, at the time of
  • Clinical diagnosis of according to the Global Initiative for Chronic Obstructive Lung Disease [GOLD] Report, 2026 for at least 12 months prior to Screening Visit 1
  • Post-bronchodilator spirometry (after 10 to 30 minutes following 4 puffs of albuterol via MDI with a spacer) at Screening Visit 2 demonstrating the following:

    • > 40 and \< 80% of predicted normal (using the Global Lung Function Initiative [GLI] 2012 reference values)
    • FEV1/forced vital capacity (FVC) ratio \< 0.70
    • ≥ 150 mL increase from pre-bronchodilator FEV1 following 4 puffs of albuterol
  • Ability to change current COPD therapy and discontinue long-acting bronchodilators, if applicable, for the duration of the trial and short-acting bronchodilators for 8 hours prior to dosing at each Treatment Visit
  • Current or former-smokers with at least 10 pack-year smoking history (eg, at least 1 pack/day for 10 years, 10 packs/day for 1 year)
  • Ability to perform reproducible spirometry according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines
  • Female participants of must not be pregnant, breast feeding or lactating and heterosexual female participants of childbearing potential must agree to use, with their partner, a male condom plus an approved method of highly effective from the time of informed consent and for 30 days following the last administered dose
  • Female participants of childbearing potential must have a negative serum or urine pregnancy test at Screening Visit 1 and a negative urine pregnancy test prior to dosing at each Treatment Visit
  • Male participants who are sexually active with a female partner of childbearing potential must use, with their partner, a male condom plus an approved method of highly effective contraception from the time of informed consent and for 30 days following the last administered dose
  • Participants must agree not to donate semen or ova/oocytes from the time of informed consent and for 30 days following the last administered dose
  • Willing and able to provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Current evidence or recent history of significant comorbidities; including cardiovascular disease (such as myocardial infarction, cardiac failure, uncontrolled hypertension, or life-threatening arrhythmias), uncontrolled diabetes, neurologic, psychiatric, hepatic, renal, immunological, or hematological conditions within the last 6 months prior to Screening Visit 1
  • Positive serum surface antigen (HBsAg), virus (HCV) antibody or (HIV) type 1 and/or 2 antibodies at Screening Visit 1
  • Lower respiratory tract infection within 6 weeks prior to Screening Visit 1
  • Recent history of hospitalization due to an exacerbation of airway disease or acute worsening of requiring antibiotic or systemic treatment within 6 months prior to Screening Visit 1
  • Other respiratory disorders: Current diagnosis of predominant asthma, lung cancer, bronchiectasis, interstitial lung disease, tuberculosis, pulmonary hypertension, or other non-specific pulmonary diseases
  • Prior lung volume reduction surgery or history of chest/lung irradiation
  • Daily oxygen therapy for > 12 hours per day
  • >35 kg/m2
  • Abnormal and 12-lead findings at Screening Visit 1
  • Current or recent history of medical conditions that are for use of an inhaled LAMA (such as urinary retention or bladder neck obstruction type symptoms, prostatic hypertrophy, or narrow-angle glaucoma) within the last 6 months prior to Screening Visit 1
  • Current or recent history (previous 12 months) of excessive use or abuse of alcohol (males >21 units per week and females >14 units per week)
  • Current evidence or history (within the past 2 years) of abusing legal drugs or use of illegal drugs or substances
  • Donation of 450 mL of blood within 8 weeks of Screening Visit 1
  • Major surgery (requiring general anaesthesia) within 6 weeks prior to Screening Visit 1, or planned surgery through the EOS Visit
  • History of of any organ system, except for localized skin cancers, within 5 years prior to Screening Visit 1
  • History of intolerance or to any of the ingredients in the formulation for AERO-001, AERO-002, AERO-007, or other aerosol medications
  • Participation in another drug trial within 30 days of the last dose, 5 half-lives or twice the duration of the biological effect, whichever is longer, prior to Screening Visit 1
  • History or high risk of noncompliance with trial visits and procedures or unsuitable for entry into the trial at the discretion of the Investigator
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    AERO-001 low dose

    Drug: AERO-001

  • Experimental
    AERO-001 medium dose

    Drug: AERO-001

  • Experimental
    AERO-001 high dose

    Drug: AERO-001

  • Experimental
    AERO-002 low dose

    Drug: AERO-002

  • Experimental
    AERO-002 medium dose

    Drug: AERO-002

  • Experimental
    AERO-002 high dose

    Drug: AERO-002

  • Experimental
    AERO-007

    Drug: AERO-007

  • Placebo comparator
    Placebo

    Drug: AERO-007

Interventions

  • DrugAERO-001

    Double-blind

  • Double-blind

  • DrugAERO-007

    Double-blind

06

What researchers measure

Primary outcomes

  1. Bronchodilation - FEV1

    Time frame: Change from baseline in FEV1 at 24 hours post-dose on Days 1 and 14

  2. Bronchodilation - FEV AUC

    Time frame: Change from baseline in FEV1 AUC(0-24 hours) on Days 1 and 14

  3. Bronchodilation - Peak FEV1

    Time frame: Peak change in FEV1 within 4 hours post-dose on Days 1 and 14

  4. Bronchodilation - time to onset of FEV1 >100mL

    Time frame: Change in FEV1 >100mL from pre-dose on Days 1 and 14

Secondary outcomes

  1. Pharmacokinetics - Cmax

    Cmax (maximum plasma concentration)

    Time frame: 0-24 hours on Days 1 and 14

  2. Pharmacokinetics - AUC

    AUC (area under the plasma concentration)

    Time frame: AUC(0-6 hours) on Days 1 and 14

  3. Pharmacokinetics - Tmax

    Tmax (time to maximum concentration)

    Time frame: Tmax on Days 1 and 14

  4. Treatment-emergent adverse events (TEAEs)

    Number of participants with TEAEs

    Time frame: Up to approximately Day 14

  5. Blood Pressure

    Number of participants with markedly abnormal changes in Blood Pressure

    Time frame: Up to approximately Day 14

  6. Heart Rate

    Number of participants with markedly abnormal changes in Heart Rate

    Time frame: Up to approximately Day 14

  7. 12-lead ECG - QT Interval corrected for Heart Rate Using Fridericia's Formula (QTcF)

    Number of participants with markedly abnormal changes in QTcF

    Time frame: Up to approximately Day 14

  8. Clinical laboratory - Hematology

    Number of participants with markedly abnormal changes in hematology parameters

    Time frame: Up to approximately Day 14

  9. Clinical laboratory - Blood Chemistry

    Number of participants with markedly abnormal changes in blood chemistry parameters

    Time frame: Up to approximately Day 14

07

Study locations

1 of 2 sites recruiting
  • Parexel
    London, United Kingdom
    Not yet recruiting
  • Medicines Evaluation Unit
    Manchester, United Kingdom
    Recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jun 2027, 8 months later.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 8 months is below that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2026
First posted
Oct 26, 2026
StartEst.
Oct 2026
Primary completionEst.
Jun 2027
CompletionEst.
Sep 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 28, 2026
Sites
2 sites added — first site in United Kingdom
Show 2 added (2 United Kingdom)
  • Parexel · London, United Kingdom
  • Medicines Evaluation Unit · Manchester, United Kingdom
Oct 28, 2026
Registered
First appeared on the registry
Oct 26, 2026
Show all 2 updates
  1. Oct 28, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in United Kingdom
    Show 2 added (2 United Kingdom)
    • Parexel · London, United Kingdom
    • Medicines Evaluation Unit · Manchester, United Kingdom
  2. Oct 26, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07896252
Lead sponsor
AeroRx Therapeutics Inc.
Responsible party
Sponsor
First posted
Oct 26, 2026
Start date
Oct 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

Study Director Medical Director
Contact
info@aerorxtherapeutics.com
+1-858-750-4717

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AERO-002

Start the discussion